Company / Operating Income per Share
Travere Therapeutics, Inc. Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$0.72
FY2025
5-year range
-$6.04 / -$0.72
FY2021-FY2025
Trend
+83.3%
vs FY2024
Sector context
#82 of 201
Health Care
What the data says
At $-0.72, Travere Therapeutics, Inc.'s operating income per share ranks #82 of 201 in the Health Care sector. Operating Income per Share has fluctuated over the past 10 years, ranging from $-6.04 in FY2023 to $-0.72 in FY2025.
Based on SEC 10-K filings.
-0.72 in FY2025.
Improved from $-6.04 to $-0.72 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#82 of 201 in Health CareTop 41% of 201This company -$0.72 Sector average -$28.56
▼
+97.5% above sector average
Key checks
Key Insights
- In FY2025, operating income per share increased 83.3% year-over-year.
- Ranks #82 out of 201 companies in the Health Care sector.
- Lowest operating income per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.72 | +83.3% |
| FY2024 | -$4.30 | +28.8% |
| FY2023 | -$6.04 | -18.0% |
| FY2022 | -$5.12 | -94.7% |
| FY2021 | -$2.63 | -41.5% |
| FY2020 | -$1.86 | -42.9% |
| FY2019 | -$1.30 | +12.1% |
| FY2018 | -$1.48 | -10.4% |
| FY2017 | -$1.34 | +38.8% |
| FY2016 | -$2.19 | -12.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026